Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Find Cricket Statistics

More Links
  • Elections 2019
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / Science News / Pfizer, BioNTech say their COVID-19 vaccine is over 90% effective
  • Science

    Pfizer, BioNTech say their COVID-19 vaccine is over 90% effective

    Siddhant Pandey
    Written by
    Siddhant Pandey
    Twitter
    Last updated on Nov 09, 2020, 07:18 pm
    Pfizer, BioNTech say their COVID-19 vaccine is over 90% effective
  • United States pharmaceutical giant Pfizer and German biotech firm BioNTech have said their COVID-19 vaccine is over 90% effective, according to initial data from a large study.

    The two drugmakers are the first to show successful data from a large-scale clinical trial for the vaccine.

    The novel coronavirus has infected 50.5 million people around the world and killed over 1.25 million.

  • In this article
    Analysis looked at first 94 infections among 43,000 volunteers Pfizer to seek emergency-use authorization from US FDA 50 million doses expected by 2020-end; 1.3 billion by 2021-end Pfizer to continue trial until 164 participants contract infection 'Significant step closer to providing people with much-needed breakthrough' Experts say data 'impressive'; await complete results Several drugmakers race to develop COVID-19 vaccines
  • Details

    Analysis looked at first 94 infections among 43,000 volunteers

    Analysis looked at first 94 infections among 43,000 volunteers
  • The initial analysis looked at first 94 confirmed cases among over 43,000 volunteers who either received two doses of the vaccine or placebo.

    Under 10% of infections were among participants who received the vaccine while over 90% of the infections were among people who received the placebo.

    The vaccine provided protection after seven days of the second dose (28 days after the first dose).

  • Emergency-use

    Pfizer to seek emergency-use authorization from US FDA

  • Pfizer has said the firm plans to seek emergency-use authorization from the US Food and Drug Administration for people aged 16 to 85.

    For this, Pfizer will need to have collected two months of safety data after receiving the second dose of the vaccine. Pfizer is expecting this marker by the third week of November.

    FDA requires at least 50% efficacy from any vaccine.

  • Availability

    50 million doses expected by 2020-end; 1.3 billion by 2021-end

  • If authorized for emergency-use, the number of doses will initially be limited.

    The companies had started manufacturing doses ahead of regulatory approval and are expected to produce 50 million doses by 2020-end—enough to vaccinate 25 million people.

    By the end of 2021, the companies hope to produce 1.3 billion doses.

    They notably have agreements with the US to provide up to 500 million doses.

  • Trials

    Pfizer to continue trial until 164 participants contract infection

    Pfizer to continue trial until 164 participants contract infection
  • The Phase III trials of Pfizer's vaccine have enrolled 43,538 participants since July 27.

    Till Sunday, 38,955 of the volunteers had received a second dose of the vaccine.

    The firm has said 42% of international trial sites and 30% of US trial sites involve volunteers of racially/ethnically diverse backgrounds.

    Pfizer said it will continue the trial until there are 164 COVID-19 cases among participants.

  • Quote

    'Significant step closer to providing people with much-needed breakthrough'

    'Significant step closer to providing people with much-needed breakthrough'
  • Pfizer CEO Albert Bourla said in a statement, "With today's news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis."

    Bourla added, "We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks."

  • Reaction

    Experts say data 'impressive'; await complete results

  • William Schaffner—an infectious diseases expert at Vanderbilt University School of Medicine—told Reuters, "The efficacy data are really impressive. This is better than most of us anticipated." Schaffner said the data looks promising, even though the study isn't complete.

    Marylyn Addo—the head of tropical medicine at the University Medical Center Hamburg-Eppendorf—added, "Primary data are not yet available and a peer-reviewed publication is still pending."

  • Other vaccines

    Several drugmakers race to develop COVID-19 vaccines

    Several drugmakers race to develop COVID-19 vaccines
  • Separately, US-based Moderna Inc.—whose mRNA vaccine is another leading candidate—is expecting the results of its large-scale trial later this month.

    Meanwhile, the interim Phase III trial data for the Oxford University and AstraZeneca's vaccine candidate is expected as early as next month. This vaccine will be sold as 'Covishield' in India.

    India's indigenous COVAXIN—developed by Bharat Biotech—is expected to be ready by February 2021.

  • Vaccine
  • United States
  • Coronavirus
  •  
Latest News
  • Records Virat Kohli can break in Test series versus England
    Records Virat Kohli can break in Test series versus England
    Sports
  • Delhi Metro schedule on Republic Day; check details here
    Delhi Metro schedule on Republic Day; check details here
    India
  • 20-year-old Srishti Goswami is Uttarakhand's CM for one day
    20-year-old Srishti Goswami is Uttarakhand's CM for one day
    India
  • Nashik farmers march to Mumbai for anti-farm law rally
    Nashik farmers march to Mumbai for anti-farm law rally
    India
Related Timelines
  • Can prepare vaccine against mutated virus in 6 weeks: BioNTech
    Can prepare vaccine against mutated virus in 6 weeks: BioNTech
    Science
  • Here's how the government is planning to conduct COVID-19 vaccinations
    Here's how the government is planning to conduct COVID-19 vaccinations
    India
  • US clears Pfizer coronavirus vaccine, first shot in 24 hours
    US clears Pfizer coronavirus vaccine, first shot in 24 hours
    World
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love Science news?

Subscribe to stay updated.

Science Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Cricket News Facebook Donald Trump Hollywood News WhatsApp Bollywood News
Elon Musk Saif Ali Khan Football News Vaccine Congress Google Amazon Apple Manchester United Sensex
Premier League Joe Biden Royal Enfield Porsche Latest Gadget Launch Latest Automobile News IPL 2021 Coronavirus MediaTek Dimensity 1000+ COVAXIN
Latest Tech News
About Us Privacy Policy Terms & Conditions Contact Us News News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021